Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 17, 2017

New clinical trial to test drug combination to treat osteogenesis imperfecta

The University of Edinburgh will conduct a six-year trial of teriparatide and zoledronic acid combination to treat a condition called osteogenesis imperfecta (OI).

The University of Edinburgh will conduct a six-year trial of teriparatide and zoledronic acid combination to treat a condition called osteogenesis imperfecta (OI). 

The study has received a £1.5m fund from the National Institute for Health Research Efficacy and Mechanism Evaluation (EME) Programme and will involve 25 hospitals in the UK and one in the Republic of Ireland, reported Pharmatimes.com.

University of Edinburgh centre for genomic and experimental medicine professor Stuart Ralston was quoted by the BBC as saying: "This is potentially a game-changing trial since it is the first study that had been specifically designed to investigate whether any treatment can prevent fractures in osteogenesis imperfecta.

"If the results are positive, it could herald a new dawn in the treatment of this rare but devastating condition."

"If the results are positive, it could herald a new dawn in the treatment of this rare but devastating condition."

OI is caused due to genetic mutations, which in turn leads to abnormalities in the collagen content of bone. It results in brittle bones, which can break easily even due to a mild trauma or sometimes for no reason, reported BBC.

The trial will assess the combination of two therapies in 390 people suffering with OI. About 50% of the patients will be administered with teriparatide followed by zoledronic acid, while the other half will be put through standatd care, reported news agencies.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Both therapies are individually validated to treat this problem and this is the first time they will be tested in combination to treat OI.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU